REINVENTING MEDICINE FOR A HEALTHIER WORLD
ULTRA-LONG-ACTING ORAL DOSING IS ACHIEVABLE
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company’s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra’s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH. For more information, visit the Company’s website at www.lyndra.com.
At Lyndra, we ask “What if we stopped trying to change the patient and changed the pill instead?"
Want to learn more? Please visit our website or contact us at info@lyndra.com.
INSPIRED to Join Our Team? Check us out and apply! www.lyndra.com/join-our-team/
At Lyndra Therapeutics, we are INSPIRED by team members who are excited by innovation and growth, demonstrate strong technical expertise, and live our values. We are looking for people who will bring fresh ideas based on experience and who lead by adapting to the fast pace of an emerging biotech.
ULTRA-LONG-ACTING ORAL DOSING IS ACHIEVABLE
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company’s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra’s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH. For more information, visit the Company’s website at www.lyndra.com.
At Lyndra, we ask “What if we stopped trying to change the patient and changed the pill instead?"
Want to learn more? Please visit our website or contact us at info@lyndra.com.
INSPIRED to Join Our Team? Check us out and apply! www.lyndra.com/join-our-team/
At Lyndra Therapeutics, we are INSPIRED by team members who are excited by innovation and growth, demonstrate strong technical expertise, and live our values. We are looking for people who will bring fresh ideas based on experience and who lead by adapting to the fast pace of an emerging biotech.
Location: United States, Massachusetts, Watertown
Employees: 51-200
Total raised: $252.5M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Old Silver... | oldsilverv... |
| 29.06.2021 | Cavendish ... | cavendishf... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 28.12.2023 | Series E | $101M | - |
| 27.06.2021 | Series C | $60.5M | - |
| 30.07.2019 | Grant | $13M | - |
| 30.01.2019 | Series B | $55M | - |
| 18.04.2017 | Series A | $23M | - |
Mentions in press and media 25
| Date | Title | Description |
| 19.08.2025 | Healthcare-focused VC W Health Ventures makes four leadership appointments | Credit: 123RF.com Healthcare-focused venture capital firm W Health Ventures, which rolled out its second flagship fund last month targeting to raise $100 million (around Rs 870 crore), has added four industry leaders to its team as it doubl... |
| 19.08.2025 | W Health Ventures Strengthens Leadership Team with Four Senior Appointments Ashish Singh, Dr. Prakash Patel, and Ajay Sondhi have joined as Operating Partners, while Mahadevan "Mahad" Naraya... | W Health Ventures has announced the appointment of four senior leaders to its leadership team as it continues to expand its healthcare-focused company creation model. Ashish Singh, Dr. Prakash Patel, and Ajay Sondhi have joined as Operating... |
| 27.03.2025 | US-based Lyndra Therapeutics ceases operations due to “insufficient funding”, says Sun Pharma | The Massachusetts-based Lyndra Therapeutics Inc “is ceasing operations from March 26th, due to insufficient funding to continue their business activities,” said Sun Pharmaceutical Industries, who is invested in the US company. In December 2... |
| 28.12.2023 | Lyndra Therapeutics: Clinical-Stage Biopharmaceutical Company Closes $101 Million | Lyndra Therapeutics – a clinical-stage biopharmaceutical company – recently announced the closing of a $101 million Series E financing round. The proceeds of the funding round, led by Sarissa Capital and including Sun Pharmaceutical Industr... |
| 21.12.2023 | Lyndra Therapeutics Raises $101M in Series E Funding | Lyndra Therapeutics, a Watertown, MA-based clinical-stage biopharmaceutical company, raised $101M in Series E funding. The round was led by Sarissa Capital and including Sun Pharmaceutical Industries Limited and Polaris Partners. The round ... |
| 21.12.2023 | Lyndra Therapeutics Closes $101M Series E | WATERTOWN, MA, Lyndra Therapeutics, a clinical-stage biopharmaceutical company, today announced the closing of a $101 million Series E financing round. >> Click here for more funding data on Lyndra >> To export Lyndra fundin... |
| 27.06.2021 | Lyndra Therapeutics Closes $60.5M Series C Financing | Lyndra Therapeutics, a Watertown, Mass.-based clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, closed a $60.5m Series C financing. Th... |
| 25.06.2021 | Does BuzzFeed know what it is? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content 3 ways universities must adapt to reach lifelong learners From 2U On Thursday, 15-ye... |
| 25.06.2021 | Does BuzzFeed know what it is? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Why the Electricity 4.0 moment is here From Schneider Electric On Thursday, 15-year-... |
| 24.06.2021 | Lyndra Therapeutics : Completes $60.5 Million Series C Financing | Lyndra Therapeutics, a clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, today announced the closing of its $60.5 million Series C fin... |
Show more